
Takeda commits to deliver 50 million doses of Moderna’s COVID-19 vaccine in Japan
pharmafile | October 29, 2020 | News story | Manufacturing and Production, Sales and Marketing | COVID-19, Japan, Moderna, Takeda, Vaccine
Takeda has made a commitment with Japan’s Ministry of Health, Labor and Welfare (MHLW) to deliver 50 million doses of Moderna’s COVID-19 mRNA-1273 vaccine, the company announced.
The commitment is dependent on whether the candidate can secure regulatory approval from the MHLW. If the vaccine is successful, Takeda will carry out importing and distribution duties to roll out the candidate to Japan’s citizens in the first half of next year.
This isn’t the first partnership of its kind that Takeda has forged to tackle the COVID-19 pandemic, having synced up with Novavax in August to aid in the development, manufacturing and commercialisation of the latter’s vaccine candidate for the virus.
“Takeda is collaborating with the Japanese Government and vaccine developers to provide rapid and sustained access to COVID-19 vaccines in Japan,” remarked Rajeev Venkayya, President of Takeda’s Global Vaccine Business Unit at Takeda. “We have chosen to work with Novavax and Moderna, both of which have promising vaccine candidates, and will continue to support the global response to COVID-19.”
The news follows Moderna’s recent announcement that its Phase 3 clinical trial to test a 100 µg dose of its vaccine had fulfilled its enrolment target, recruiting 30,000 participants.
Matt Fellows
Related Content

BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …






